Illinois Municipal Retirement Fund Increases Stock Position in Krystal Biotech, Inc. $KRYS

Illinois Municipal Retirement Fund lifted its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 11.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,151 shares of the company’s stock after buying an additional 1,452 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Krystal Biotech were worth $3,655,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. UMB Bank n.a. boosted its position in shares of Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after purchasing an additional 37 shares in the last quarter. Optimize Financial Inc increased its holdings in shares of Krystal Biotech by 1.4% in the 4th quarter. Optimize Financial Inc now owns 2,855 shares of the company’s stock valued at $704,000 after purchasing an additional 40 shares in the last quarter. Perigon Wealth Management LLC increased its holdings in shares of Krystal Biotech by 0.5% in the 4th quarter. Perigon Wealth Management LLC now owns 8,970 shares of the company’s stock valued at $2,211,000 after purchasing an additional 41 shares in the last quarter. Regal Investment Advisors LLC lifted its stake in shares of Krystal Biotech by 1.0% in the fourth quarter. Regal Investment Advisors LLC now owns 4,360 shares of the company’s stock valued at $1,075,000 after purchasing an additional 44 shares during the period. Finally, Torray Investment Partners LLC lifted its stake in shares of Krystal Biotech by 0.4% in the first quarter. Torray Investment Partners LLC now owns 12,032 shares of the company’s stock valued at $3,108,000 after purchasing an additional 47 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insider Activity at Krystal Biotech

In related news, EVP John Charles Thomas sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the sale, the executive vice president owned 1,000 shares of the company’s stock, valued at approximately $347,270. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the sale, the insider owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. This trade represents a 1.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 26,642 shares of company stock valued at $8,243,923 over the last 90 days. Insiders own 13.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on KRYS. Bank of America boosted their price target on Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $474.00 price objective on shares of Krystal Biotech in a research note on Monday, July 13th. HC Wainwright lifted their price objective on Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a report on Tuesday, June 16th. Evercore reiterated an “outperform” rating and set a $300.00 target price on shares of Krystal Biotech in a research report on Tuesday, May 5th. Finally, TD Cowen upped their target price on Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a report on Thursday, June 18th. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $360.67.

Krystal Biotech Trading Up 3.8%

Shares of KRYS opened at $354.86 on Friday. Krystal Biotech, Inc. has a 12-month low of $130.50 and a 12-month high of $382.54. The stock has a market cap of $10.46 billion, a P/E ratio of 47.44 and a beta of 0.50. The company has a 50-day moving average of $331.38 and a two-hundred day moving average of $289.47.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, beating the consensus estimate of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The business had revenue of $116.36 million for the quarter, compared to analyst estimates of $112.11 million. As a group, analysts forecast that Krystal Biotech, Inc. will post 7.41 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.